|
1
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
2
|
Semenza GL: Hypoxia and cancer. Cancer
Metastasis Rev. 26:223–224. 2007. View Article : Google Scholar
|
|
3
|
Noda T, Yamamoto H, Takemasa I, et al:
PLOD2 induced under hypoxia is a novel prognostic factor for
hepatocellular carcinoma after curative resection. Liver Int.
32:110–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maxwell PH and Ratcliffe PJ: Oxygen
sensors and angiogenesis. Semin Cell Dev Biol. 13:29–37. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pugh CW and Ratcliffe PJ: Regulation of
angiogenesis by hypoxia: role of the HIF system. Nat Med.
9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
7
|
Zhong H, De Marzo AM, Laughner E, et al:
Overexpression of hypoxia-inducible factor 1alpha in common human
cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
8
|
Uemura M, Yamamoto H, Takemasa I, et al:
Jumonji domain containing 1A is a novel prognostic marker for
colorectal cancer: in vivo identification from hypoxic tumor cells.
Clin Cancer Res. 16:4636–4646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wada H, Nagano H, Yamamoto H, et al:
Expression pattern of angiogenic factors and prognosis after
hepatic resection in hepatocellular carcinoma: importance of
angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int.
26:414–423. 2006. View Article : Google Scholar
|
|
10
|
Yamada D, Kobayashi S, Yamamoto H, et al:
Role of the hypoxia-related gene, JMJD1A, in hepatocellular
carcinoma: clinical impact on recurrence after hepatic resection.
Ann Surg Oncol. 19(Suppl 3): S355–S364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng AL, Kang YK, Chen Z, et al: Efficacy
and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.
2009. View Article : Google Scholar
|
|
13
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vihanto MM, Plock J, Erni D, Frey BM, Frey
FJ and Huynh-Do U: Hypoxia up-regulates expression of Eph receptors
and ephrins in mouse skin. FASEB J. 19:1689–1691. 2005.PubMed/NCBI
|
|
15
|
Yamashita T, Ohneda K, Nagano M, et al:
Hypoxia-inducible transcription factor-2alpha in endothelial cells
regulates tumor neovascularization through activation of ephrin A1.
J Biol Chem. 283:18926–18936. 2008. View Article : Google Scholar
|
|
16
|
Bartley TD, Hunt RW, Welcher AA, et al:
B61 is a ligand for the ECK receptor protein-tyrosine kinase.
Nature. 368:558–560. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Holzman LB, Marks RM and Dixit VM: A novel
immediate-early response gene of endothelium is induced by
cytokines and encodes a secreted protein. Mol Cell Biol.
10:5830–5838. 1990.PubMed/NCBI
|
|
18
|
Brantley DM, Cheng N, Thompson EJ, et al:
Soluble Eph A receptors inhibit tumor angiogenesis and progression
in vivo. Oncogene. 21:7011–7026. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pandey A, Shao H, Marks RM, Polverini PJ
and Dixit VM: Role of B61, the ligand for the Eck receptor tyrosine
kinase, in TNF-alpha-induced angiogenesis. Science. 268:567–569.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng N, Brantley DM, Liu H, et al:
Blockade of EphA receptor tyrosine kinase activation inhibits
vascular endothelial cell growth factor-induced angiogenesis. Mol
Cancer Res. 1:2–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deroanne C, Vouret-Craviari V, Wang B and
Pouyssegur J: EphrinA1 inactivates integrin-mediated vascular
smooth muscle cell spreading via the Rac/PAK pathway. J Cell Sci.
116:1367–1376. 2003. View Article : Google Scholar
|
|
22
|
Ogawa K, Pasqualini R, Lindberg RA, Kain
R, Freeman AL and Pasquale EB: The ephrin-A1 ligand and its
receptor, EphA2, are expressed during tumor neovascularization.
Oncogene. 19:6043–6052. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abraham S, Knapp DW, Cheng L, et al:
Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary
bladder. Clin Cancer Res. 12:353–360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brantley-Sieders DM, Fang WB, Hwang Y,
Hicks D and Chen J: Ephrin-A1 facilitates mammary tumor metastasis
through an angiogenesis-dependent mechanism mediated by EphA
receptor and vascular endothelial growth factor in mice. Cancer
Res. 66:10315–10324. 2006. View Article : Google Scholar
|
|
25
|
Liu DP, Wang Y, Koeffler HP and Xie D:
Ephrin-A1 is a negative regulator in glioma through downregulation
of EphA2 and FAK. Int J Oncol. 30:865–871. 2007.PubMed/NCBI
|
|
26
|
Nakamura R, Kataoka H, Sato N, et al:
EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci.
96:42–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nasreen N, Mohammed KA, Lai Y and Antony
VB: Receptor EphA2 activation with ephrinA1 suppresses growth of
malignant mesothelioma (MM). Cancer Lett. 258:215–222. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Noblitt LW, Bangari DS, Shukla S, et al:
Decreased tumorigenic potential of EphA2-overexpressing breast
cancer cells following treatment with adenoviral vectors that
express Ephrin-A1. Cancer Gene Ther. 11:757–766. 2004. View Article : Google Scholar
|
|
29
|
Yamamoto H, Kondo M, Nakamori S, et al:
JTE-522, a cyclooxygenase-2 inhibitor, is an effective
chemopreventive agent against rat experimental liver fibrosis1.
Gastroenterology. 125:556–571. 2003.PubMed/NCBI
|
|
30
|
Yoshioka S, Takemasa I, Nagano H, et al:
Molecular prediction of early recurrence after resection of
hepatocellular carcinoma. Eur J Cancer. 45:881–889. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Holm R, de Putte GV, Suo Z, Lie AK and
Kristensen GB: Expressions of EphA2 and EphrinA-1 in early squamous
cell cervical carcinomas and their relation to prognosis. Int J Med
Sci. 5:121–126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamamoto H, Tei M, Uemura M, et al:
Ephrin-A1 mRNA is associated with poor prognosis of colorectal
cancer. Int J Oncol. 42:549–555. 2013.PubMed/NCBI
|
|
33
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iida H, Honda M, Kawai HF, et al:
Ephrin-A1 expression contributes to the malignant characteristics
of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut.
54:843–851. 2005. View Article : Google Scholar
|
|
35
|
Cui XD, Lee MJ, Yu GR, et al: EFNA1 ligand
and its receptor EphA2: potential biomarkers for hepatocellular
carcinoma. Int J Cancer. 126:940–949. 2010.PubMed/NCBI
|
|
36
|
Miyazaki T, Kato H, Fukuchi M, Nakajima M
and Kuwano H: EphA2 overexpression correlates with poor prognosis
in esophageal squamous cell carcinoma. Int J Cancer. 103:657–663.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zelinski DP, Zantek ND, Stewart JC,
Irizarry AR and Kinch MS: EphA2 overexpression causes tumorigenesis
of mammary epithelial cells. Cancer Res. 61:2301–2306.
2001.PubMed/NCBI
|
|
38
|
Zeng G, Hu Z, Kinch MS, et al: High-level
expression of EphA2 receptor tyrosine kinase in prostatic
intraepithelial neoplasia. Am J Pathol. 163:2271–2276. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Walker-Daniels J, Riese DJ 2nd and Kinch
MS: c-Cbl-dependent EphA2 protein degradation is induced by ligand
binding. Mol Cancer Res. 1:79–87. 2002.PubMed/NCBI
|
